Adult Clinical Trials

Melanoma and other skin cancers

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Melanoma Clinical Trials Office at 919.684.8239.

8 trials identified.

Proleukin Observational Registry to Evaluate the Treatment Patterns and Clincal Response in Malignancy
Phase: N/A
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Michael Morse
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00032008

AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE 1B/2 STUDY OF THE SAFETY, EFFICACY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF RTA 408 IN COMBINATION WITH IPILIMUMAB OR NIVOLUMAB IN THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00059068
View this trial at ClinicalTrials.gov

A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00059334
View this trial at ClinicalTrials.gov

Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Brent Hanks
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00059349

A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody -Drug Conjugate, as Monotherapy or in Combination with Immunotherapies in Patients with Advanced Melanoma
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00065547
View this trial at ClinicalTrials.gov

A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: April Salama
Contact: Melanoma Clinical Trials Research Office
Phone: 919 .613.0400
Reference Number: 00067271
View this trial at ClinicalTrials.gov

A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC in stage III and stage IV (resected) melanoma to prevent recurrence
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Stewart
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00068598
View this trial at ClinicalTrials.gov

A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Dan Blazer
Contact: Melanoma Clinical Trials Research Office
Phone: 919.613.0400
Reference Number: 00069107
View this trial at ClinicalTrials.gov